Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Short answer: Menopausal hormone therapy (MHT) is the most effective treatment for hot flashes and night sweats, and systemic therapy prevents bone loss and lowers fracture risk while it is being used. It is not recommended as a medicine to prevent heart disease or other chronic conditions in people who have no menopause symptoms. Heart, clot, cancer, and stroke risks depend on the person, the formulation, the route, the dose, the duration, age, and time since menopause.
People with bothersome symptoms who are younger than 60 or within 10 years of menopause often have a more favorable benefit–risk balance after individualized counseling, but that timing does not override contraindications. A uterus, a history of blood clots or cardiovascular disease, unexplained bleeding, liver disease, cancer history, family history, and personal preferences all change the discussion. This guide explains what the evidence supports, where it does not, and what alternatives to discuss with a clinician.
Does hormone therapy help your heart or bones?
The answer differs by outcome. Systemic MHT can relieve vasomotor symptoms such as hot flashes and night sweats, treat other menopause-related symptoms, prevent bone loss, and reduce fractures. Those are treatment or risk-reduction benefits. They are different from taking hormones solely to prevent a future heart attack, stroke, dementia, or another chronic condition when you do not have symptoms.
| Question | What current guidance supports |
|---|---|
| Can MHT prevent heart disease? | No. Professional guidance does not recommend starting systemic MHT solely for primary prevention of cardiovascular disease or other chronic conditions in an asymptomatic person. |
| Can MHT protect bones? | Yes. Systemic MHT prevents bone loss and has been shown to reduce fractures. Whether it is the right osteoporosis strategy depends on fracture risk, age, bone-density results, medical history, and other treatment options. |
| What is MHT best at treating? | Systemic MHT is the most effective treatment for hot flashes and night sweats. Low-dose vaginal estrogen is a separate, local option for genitourinary symptoms. |
The Menopause Society’s 2024 statement cautions that ovarian hormones do not need to be routinely “replaced” in people undergoing menopause at the average age. Treatment is a choice for a specific symptom or indication, not an automatic requirement of menopause.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
What menopausal hormone therapy is—and what it is not
MHT supplies estrogen, with a progestogen when needed to protect the uterine lining. Products may be systemic, meaning the medicine reaches the bloodstream and many organs, or local, meaning exposure is concentrated in vaginal tissues.
Systemic therapy
Systemic estrogen is available as oral medication and as transdermal patches, gels, or sprays. It is used when symptoms affect the whole body, including hot flashes, night sweats, and some sleep or quality-of-life problems linked to those symptoms. Systemic treatment also has a bone-preserving effect.
The Menopause Society’s 2022 position statement says transdermal routes and lower doses may reduce venous thromboembolism and stroke risk compared with some oral regimens. “May reduce” is a relative-risk statement, not a promise that a patch, gel, spray, or low dose is risk-free.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Local vaginal therapy
Low-dose vaginal estrogen is designed for genitourinary symptoms such as vaginal dryness, irritation, painful sex, or urinary symptoms. It is not equivalent to a systemic dose and should not be presented as a substitute for systemic treatment of hot flashes or as a heart-prevention drug. The product’s route, dose, labeling, and a person’s medical history determine whether it is appropriate.
Does hormone therapy prevent heart disease?
No. Do not start systemic MHT solely to prevent a first heart attack, stroke, or other chronic disease.
The U.S. Preventive Services Task Force (USPSTF) recommends against using systemic estrogen plus progestin for primary prevention of chronic conditions in postmenopausal people with a uterus and against systemic estrogen alone for those who have had a hysterectomy. The recommendation addresses people who are not seeking treatment for menopause symptoms. It does not apply to symptom relief, premature or primary ovarian insufficiency, or surgical menopause.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
The Menopause Society’s 2024 statement likewise says estrogen-containing therapy is not recommended for primary prevention of cardiovascular disease in people who experience menopause at the average age. Research and professional guidance discuss how age, years since menopause, baseline health, formulation, and route can influence outcomes. Those timing observations do not establish MHT as a prevention strategy.
Recommended Free Tools
Why timing is discussed
For many healthy symptomatic people who begin systemic MHT before age 60 or within 10 years of menopause onset, professional guidance describes a generally more favorable overall benefit–risk balance than for someone starting much later. That statement concerns treatment of symptoms after an individualized review. It is not a cardiovascular-prevention indication, and it does not erase a history of clotting, stroke, cardiovascular disease, cancer, liver disease, or unexplained bleeding.
What the WHI formulation does—and does not—tell you
The USPSTF describes the Women’s Health Initiative trial regimen as 0.625 mg per day of oral conjugated equine estrogen, with or without 2.5 mg per day of medroxyprogesterone acetate. Those doses and products identify a particular trial; they are not a recommendation and do not represent every current estrogen, progestogen, route, or dose.
Can hormone therapy prevent osteoporosis?
Yes. Systemic MHT prevents postmenopausal bone loss and has been shown to reduce fractures. Prevention of osteoporosis is an FDA-approved indication described by the USPSTF, alongside treatment of menopausal symptoms.
The bone benefit does not mean every person with low bone density should use MHT. A clinician must interpret bone-density testing, prior or current fractures, age, family history, other illnesses, medicines, fall risk, and kidney or gastrointestinal considerations. A diagnosis of osteoporosis may call for an osteoporosis-specific medicine, monitoring plan, or another approach rather than MHT.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →What a bone-health evaluation usually addresses
- Whether a bone-density test is indicated and how the result fits your age and fracture history.
- Whether a prior fracture or calculated fracture risk warrants pharmacologic treatment.
- Which approved osteoporosis therapies fit your medical conditions and preferences.
- How to address calcium, vitamin D, exercise, fall prevention, smoking, alcohol, and other modifiable factors without treating supplements as a replacement for evaluation.
- When repeat testing and follow-up are needed.
ACOG’s Clinical Practice Guideline No. 2, “Management of Postmenopausal Osteoporosis,” published in April 2022 and reaffirmed in 2026, covers pharmacotherapy, monitoring, follow-up, and the roles of calcium and vitamin D. Ask for an individualized plan rather than selecting a supplement regimen from a generic checklist.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Who may consider systemic MHT?
Professional guidance generally finds that benefits outweigh risks for many healthy symptomatic people younger than 60 or within 10 years of menopause onset, after shared decision-making. The decision should match the treatment goal: symptom relief, prevention of bone loss, or both.
Typical-age menopause with symptoms
For bothersome hot flashes, night sweats, or other systemic symptoms, discuss the lowest effective dose and a route and regimen that fit your risk profile. There is no universal duration that applies to everyone. Reassess benefits, risks, symptoms, and alternatives periodically instead of assuming treatment must continue indefinitely or must stop at a fixed age.
Premature ovarian insufficiency, early menopause, or surgical menopause
These situations require separate reasoning. The Menopause Society’s 2022 statement notes that prolonged estrogen deficiency is associated with greater bone-loss and heart-disease risks in primary ovarian insufficiency and recommends considering MHT until at least the mean age of menopause unless contraindicated. Do not generalize that recommendation to typical-age menopause, and do not stop or start therapy without specialist guidance.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Asymptomatic people seeking prevention
If you have no menopause symptoms and are considering hormones to prevent heart disease, dementia, or “aging,” the USPSTF recommendation against systemic MHT for primary prevention applies. A bone indication, premature ovarian insufficiency, or surgical menopause is a different clinical question.
How uterus status changes the regimen
If you have a uterus, systemic estrogen generally needs an adequate progestogen to protect the endometrium. Estrogen without sufficient progestogen can stimulate the uterine lining and increase endometrial-cancer concerns. A person who has had a hysterectomy may be able to use estrogen-only therapy, but that is a different risk–benefit situation and still requires a medical review.
| Uterine status | Typical discussion | Important qualification |
|---|---|---|
| Uterus present | Systemic estrogen is generally paired with a progestogen. | Unexpected bleeding requires evaluation; the regimen must adequately protect the endometrium. |
| Hysterectomy | Estrogen-only systemic therapy may be considered in some people. | Past cancer, endometriosis, residual tissue, cardiovascular risk, and other factors still matter. |
| No systemic symptoms; genitourinary symptoms only | Low-dose local vaginal therapy may be considered. | Local therapy is not interchangeable with systemic treatment. |
What are the benefits and risks of MHT?
Potential benefits
- Most effective relief for hot flashes and night sweats.
- Improvement of other menopause symptoms for some people.
- Prevention of bone loss and reduction in fractures while systemic therapy is used.
- Local relief of genitourinary symptoms with low-dose vaginal estrogen.
- For selected people with premature ovarian insufficiency or surgical menopause, replacement of missing ovarian hormones may address the health effects of prolonged estrogen deficiency until around the usual menopause age, unless contraindicated.
Risks that require individualized review
Professional guidance discusses stroke, venous blood clots, breast-cancer considerations that vary by regimen and duration, and uterine or endometrial cancer concerns when estrogen is used without adequate progestogen in someone with a uterus. Risk is not one fixed number for all products or all people. Oral versus transdermal delivery, dose, estrogen and progestogen choice, duration, age, time since menopause, and personal history can change the balance.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
A personal history of breast or uterine cancer, unexplained vaginal bleeding, liver disease, blood clots, or cardiovascular disease merits careful review and may make systemic MHT unsuitable. Some people need input from a menopause specialist, gynecologist, cardiologist, hematologist, or oncologist. Do not interpret a general statement about “healthy women” as clearance for your own medical history.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesCompounded “bioidentical” hormones
Custom-compounded products have not been shown to be safer or more effective than approved products. The Menopause Society warns that compounded hormones may have unpredictable absorption or dosing and may lack adequate evidence on safety and effectiveness. A compounded product is not a safer workaround for a contraindication or a way to avoid monitoring.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What changed in FDA labeling in 2025 and 2026?
FDA’s November 10, 2025 announcement requested labeling changes for menopausal hormone therapy products, including removal of specified boxed-warning language about cardiovascular disease, breast cancer, and probable dementia, along with other proposed changes. A request was not the same as every product label already changing.
On February 12, 2026, FDA reported approving label changes for six MHT products. The affected group included systemic combination products, systemic estrogen-alone products, a systemic progestogen-alone product, and a topical vaginal estrogen product. FDA said the specified cardiovascular disease, breast cancer, and probable dementia statements were removed from the boxed warning for those products.
These actions were product-specific at that point. Check the current prescribing information for the exact medicine being considered; do not assume all MHT products have identical labels. A boxed warning is only one part of a label and is not a complete risk profile. The Menopause Society’s November 2025 response emphasized that systemic estrogen still has potential risks for certain individuals and that medical history and preferences must be reviewed.
The label changes do not cancel the USPSTF recommendation against systemic MHT for primary prevention of chronic conditions and do not establish MHT as a cardiovascular-prevention medicine.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
What are the alternatives if you cannot or do not want to take hormones?
For hot flashes and night sweats
The Menopause Society’s 2023 nonhormone therapy position statement is intended for people who cannot use MHT or prefer not to. It reviews evidence-based nonhormonal treatment options. Ask a clinician to match an option to your symptoms, other medicines, blood pressure, sleep, mental health, migraine pattern, and personal preferences. Avoid assuming that every supplement, “natural” product, or lifestyle program has the same evidence or effectiveness as established treatments.
When discussing nonhormonal care, ask:
- What outcome is the treatment expected to improve, and how quickly should it work?
- What side effects, interactions, or contraindications apply to me?
- What evidence supports this particular product or intervention?
- How will we decide whether to continue, change, or stop it?
For genitourinary symptoms
Options depend on the symptom and its severity. Local vaginal estrogen is one hormonal option with local exposure; other prescription or nonprescription approaches may be appropriate for some people. A history of cancer, bleeding, recurrent urinary symptoms, or pain with sex warrants evaluation rather than self-treatment alone.
For bone protection
Separate prevention from treatment of diagnosed osteoporosis. Ask about bone-density assessment, fracture-risk calculation, approved osteoporosis medicines, exercise and fall prevention, and the roles of calcium and vitamin D. ACOG’s osteoporosis guideline provides a framework for medication selection, monitoring, and follow-up. Do not substitute a generic supplement stack for a fracture-risk assessment.
How to prepare for a clinician conversation
- Define the goal. Write down whether you want help with hot flashes, night sweats, sleep disruption, genitourinary symptoms, bone loss, or several problems. If prevention is your only goal, say that explicitly.
- Record menopause timing. Note your age, the date of your last menstrual period if known, whether menopause followed surgery or cancer treatment, and any history of primary ovarian insufficiency.
- List your medical and family history. Include breast or uterine cancer, unexplained bleeding, blood clots, stroke, heart disease, liver disease, migraine, high blood pressure, osteoporosis, fractures, and close relatives’ clotting or cancer history.
- Bring every medicine and supplement. Include doses, nonprescription products, compounded hormones, and medicines prescribed by other clinicians.
- Discuss formulation and route. Ask whether oral, transdermal, or local therapy is being considered; whether a progestogen is needed; and what dose and duration are reasonable for your goal.
- Agree on monitoring. Clarify which symptoms, bleeding patterns, blood-pressure readings, tests, or follow-up visits should trigger a call or a change in treatment.
- Review alternatives. Ask what nonhormonal treatment or osteoporosis-specific therapy would offer, what evidence supports it, and what you would do if the first option fails.
Do not self-prescribe, abruptly stop, or change the dose or route of MHT without the prescriber who knows your history. Seek prompt medical evaluation for new unexplained bleeding, chest pain, sudden shortness of breath, one-sided leg swelling, or neurologic symptoms.
Key numbers and context
- The Menopause Society reported that fewer than 4% of women aged 50 to 59 used hormone therapy in 2023. That is a utilization figure, not the percentage who need treatment or a measure of appropriate use.
- The USPSTF notes that natural menopause occurs at a median age of 51.3 years. This is context, not a treatment threshold.
- The WHI regimen described by the USPSTF used 0.625 mg/day oral conjugated equine estrogen, with or without 2.5 mg/day medroxyprogesterone acetate. It was a trial-specific formulation, not a universal current dose.
Bottom line for decision-making
Use systemic MHT when there is a clear, individualized indication—most often bothersome symptoms, and in some cases prevention of bone loss—after weighing route, dose, uterus status, age, time since menopause, medical history, and preferences. Do not use it solely to prevent heart disease or other chronic conditions in an asymptomatic person. Local vaginal therapy is a different treatment from systemic MHT. FDA label changes in 2025–2026 modify warnings for specified products but do not remove all risks or turn MHT into a heart-prevention drug.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
